NCT02472054View on ClinicalTrials.gov

Treatment of Familiar Lymphohistiocytosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

June 29, 2015

Primary Completion Date

September 12, 2019

Study Completion Date

May 20, 2020

Conditions
Hemophagocytic Lymphohistiocytosis (HLH)
Interventions
DRUG

Alemtuzumab

DRUG

Methyl Prednisolone (MP)

DRUG

Cyclosporin A (CSA)

Trial Locations (1)

75015

Hôpital Necker-Enfants Malades, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02472054 - Treatment of Familiar Lymphohistiocytosis | Biotech Hunter | Biotech Hunter